Send the following on WhatsApp
Continue to Chathttps://it.marketscreener.com/quotazioni/azione/GENEURO-SA-27100923/attualita/GeNeuro-presentera-i-dati-di-sicurezza-ed-efficacia-di-Fase-IIb-su-Temelimab-derivanti-dallo-studi-42078544/?utm_source=whatsapp&utm_medium=social&utm_campaign=share